Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.5 EUR
339.54 M EUR
2.96 B EUR
148.38 M
About Hikma Pharmaceuticals Plc
Sector
Industry
CEO
Riad Mishlawi
Website
Headquarters
London
Founded
1978
ISIN
GB00B0LCW083
FIGI
BBG000KRDHB3
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Hikma Pharmaceuticals Plc stocks are traded under the ticker H5P.
We've gathered analysts' opinions on Hikma Pharmaceuticals Plc future price: according to them, H5P price has a max estimate of 32.72 EUR and a min estimate of 24.91 EUR. Watch H5P chart and read a more detailed Hikma Pharmaceuticals Plc stock forecast: see what analysts think of Hikma Pharmaceuticals Plc and suggest that you do with its stocks.
Yes, you can track Hikma Pharmaceuticals Plc financials in yearly and quarterly reports right on TradingView.
Hikma Pharmaceuticals Plc is going to release the next earnings report on Feb 19, 2026. Keep track of upcoming events with our Earnings Calendar.
H5P net income for the last half-year is 213.90 M EUR, while the previous report showed 124.52 M EUR of net income which accounts for 71.77% change. Track more Hikma Pharmaceuticals Plc financial stats to get the full picture.
Hikma Pharmaceuticals Plc dividend yield was 3.11% in 2024, and payout ratio reached 48.77%. The year before the numbers were 3.17% and 81.97% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 6, 2025, the company has 9.5 K employees. See our rating of the largest employees — is Hikma Pharmaceuticals Plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Hikma Pharmaceuticals Plc EBITDA is 633.19 M EUR, and current EBITDA margin is 25.71%. See more stats in Hikma Pharmaceuticals Plc financial statements.
Like other stocks, H5P shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hikma Pharmaceuticals Plc stock right from TradingView charts — choose your broker and connect to your account.